AstraZeneca Details Findings in Drug Development (Multidisciplinary Considerations for Implementing Bayesian Borrowing In Basket Trials).

AstraZeneca has published a report on drug development, highlighting the use of basket trials as a new approach. Traditionally, clinical trials focused on participants with the same disease, but the discovery of common therapeutic targets across different diseases has led to the development of basket trials. These trials allow for the evaluation of one therapy across multiple related diseases, using statistical tools like Bayesian borrowing to borrow information across diseases. The report provides a framework for implementing Bayesian borrowing in basket trials for successful drug development. [Extracted from the article]

Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)